Table 3.
Summary of ongoing clinical trials evaluating oncolytic virotherapy in combination with immune checkpoint inhibition.
| Oncolytic virus and NCT number | Combination | Status |
|---|---|---|
| Herpes Simplex Virus-1 (HSV-1) | ||
| NCT04185311 | T-Vec + Ipilimumab + Nivolumab | Active, not recruiting. Phase 1. Neo-adjuvant, breast cancer (TNBC, ER+HER2-) |
| NCT03842943 | T-Vec + Pembrolizumab | Recruiting. Phase 2, neo-adjuvant, stage 3 resectable melanoma |
| NCT04068181 | T-Vec + Pembrolizumab | Active, not recruiting. Phase 2, metastatic melanoma following progression on anti-PD1 therapy |
| NCT03069378 | T-Vec + Pembrolizumab | Recruiting. Metastatic/locally advanced sarcoma |
| NCT02509507 | T-Vec + Pembrolizumab | Recruiting, phase 1b/2. Liver tumours (HCC and liver metastases) |
| NCT04050436 | RP1 + Cemiplimab | Recruiting |
| Phase II | ||
| Locally advanced or metastatic cutaneous SCC (CSCC) | ||
| NCT03767348 | RP1 + Nivolumab | Recruiting |
| Phase 1/2 | ||
| Advanced and/or refractory solid tumours | ||
| NCT04336241 | RP2 + Nivolumab | Recruiting |
| Phase 1, advanced solid tumours | ||
| NCT04735978 | RP3 + Nivolumab | Recruiting |
| Phase 1, advanced solid tumours | ||
| NCT04348916 | ONCR-177 + Pembrolizumab | Recruiting. Phase 1, advanced solid tumours and liver metastases |
| Adenovirus | ||
| NCT04387461 | Intravesical CG0070 + Pembrolizumab | Recruiting |
| Phase 2, non-muscle invasive bladder cancer | ||
| NCT02636036 | Enadenotucirev + Nivolumab | Active, not recruiting |
| Phase 1, metastatic or advanced epithelial tumours | ||
| NCT02798406 | DNX-2401 + Pembrolizumab | Active, not recruiting |
| Phase 2, glioblastoma and gliosarcoma | ||
| NCT04123470 | LOAd703 + Atezolizumab | Recruiting |
| Phase 1/2, Metastatic melanoma | ||
| NCT02705196 | LOAd703 + Atezolizumab + standard of care (Gemcitabine/nab-Paclitaxel) | Recruiting. Phase 1/2. Pancreatic cancer. |
| NCT03172819 | OBP-301 + Pembrolizumab | Active, not recruiting |
| Phase 1, advanced or metastatic solid tumours | ||
| NCT03921021 | OBP-301 + Pembrolizumab | Recruiting |
| Phase 2, esophagogastric adenocarcinoma | ||
| NCT03003676 | ONCOS 102 + Pembrolizumab | Active, not recruiting. Phase 1, advanced melanoma after progression on anti-PD-1 therapy |
| NCT02963831 | ONCOS 102 (intraperitoneal) + Durvalumab | Recruiting, phase II |
| Vaccinia virus | ||
| NCT03294083 | Pexa-Vec (JX-594) + Cemiplimab | Recruiting, phase 1b/2a, metastatic or unresectable RCC |
| NCT02977156 | Pexa-Vec (JX-594) + Ipilimumab | Recruiting, phase 1, advanced solid tumours |
| Poliovirus | ||
| NCT04577807 | PVSRIPO + Nivolumab | Phase 2. Advanced, PD1 refractory melanoma |
| NCT03973879 | PVSRIPO + Atezolizumab | Withdrawn (resubmission planned), phase 1/2 glioma |
| VSV | ||
| NCT02923466 | VSV-OFNb-NIS + Avelumab | Active, not recruiting. Phase 1, refractory solid tumours |